Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 18, 2017
Pharmacy Choice - Pharmaceutical News - Janssen Pharmaceutical Companies - Idylla Respiratory Panel receives 510 clearance by US FDA - November 18, 2017

Pharmacy News Article

 9/7/17 - Janssen Pharmaceutical Companies - Idylla Respiratory Panel receives 510 clearance by US FDA

Release date- 06092017 - Beerse, Belgium - Janssen Diagnostics, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that the United States Food and Drug Administration has granted 510(k) clearance for the Idylla Respiratory (IFV-RSV) Panel, a diagnostic test developed by Janssen Diagnostics scientists in partnership with Biocartis Group NV.

The test offers fast and easy access to molecular diagnostic information and can assist physicians in identifying viral respiratory infections in patients, and thereby enable treatment selection.

The new diagnostic test facilitates the diagnosis of infection from Respiratory Syncytial Virus (RSV) and Influenza virus (IFV) through the detection of a wide array of pathogens, including Influenza A, Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype 2009 H1, H275Y mutation of Influenza A subtype 2009 H1, Influenza B and Respiratory Syncytial Virus (A and B). The assay uses samples from nasopharyngeal swabs in Viral Transport Media of adult and pediatric patients and is processed on the Idylla system, a fully automated multiplex polymerase chain reaction diagnostic platform that provides results for the IFV-RSV Panel in approximately 50 minutes with less than 2 minutes hands-on time.

IFV and RSV are among the most common human respiratory viral infections and are associated with significant morbidity and mortality globally. Three to five million individuals worldwide develop severe influenza and 250,000 to 500,000 die of Flu-related causes annually.1 RSV has been estimated to infect 34 million young children each year and causes up to 199,000 fatalities.2

'We are very pleased to receive this 510(k) clearance for the Idylla Respiratory (IFV-RSV) Panel,' commented Werner Verbiest, Global Head, Janssen Diagnostics, LLC. 'We hope this innovative diagnostic test will help physicians in the U.S. develop more precise and personalized treatment strategies to help patients facing these widespread and potentially fatal viruses.'

About the Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it.


Frederik Wittock

Tel: +32(0)14 60 57 24

(c) 2017 Electronic News Publishing -

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 19: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement